Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology biological products, has recently published a peer-reviewed article in the Journal of Dermatological Treatment. The article confirms the disease-modifying potential of PC111, a first-in-class human anti-Fas Ligand monoclonal antibody. This development is significant as it demonstrates PC111's ability to prevent blister formation in humanized models of pemphigus by targeting soluble Fas Ligand, presenting a novel, non-immunosuppressive approach to treatment.
The study's findings also suggest potential applications for PC111 in treating Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), a life-threatening dermatological condition. Amir Reichman, CEO of Scinai Immunotherapeutics, emphasized that these results underscore PC111's capability to revolutionize treatment for these conditions, which currently have high unmet medical needs, thereby offering substantial benefits to patients and shareholders alike.
For further details on this groundbreaking research, the full press release can be accessed here. This publication marks a pivotal step forward in the development of innovative treatments for severe dermatological diseases, potentially improving the quality of life for patients worldwide.
